Ritonavir
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Ritonavir
- Ritonavir: From Unspecified Original Indication to Feline Acquired Immunodeficiency Syndrome
Ritonavir: From Unspecified Original Indication to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Ritonavir's original indication and mechanism of action are not documented in this evidence pack (flagged as data gaps DG001/DG002). The TxGNN model predicts a possible association with Feline Acquired Immunodeficiency Syndrome (score 99.92%), but this is supported by only 1 clinical trial — which studies human HIV-1, not feline AIDS — and 0 directly relevant publications.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (original_indications: []) |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome |
| TxGNN Prediction Score | 99.92% (rank 1134) |
| Evidence Level | L5 — the only associated trial does not study the predicted (feline) indication; no literature |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (Data Gap DG002, High severity). The drug's original indication history is also not documented (original_indications is empty), so the relationship between ritonavir's established use and the predicted new indication cannot be verified from the supplied data alone.
Separately, the predicted indication itself — feline acquired immunodeficiency syndrome — is a veterinary disease of cats (caused by feline immunodeficiency virus, FIV), not a human condition. The single clinical trial attached as supporting evidence (NCT02770508) actually enrolls human HIV-1 patients, not cats with FIV infection. This population mismatch suggests the TxGNN score likely reflects knowledge-graph embedding similarity between lentiviral disease nodes (HIV-1 ~ FIV) rather than direct clinical support for using ritonavir in feline AIDS. Without confirmed MOA data and without any veterinary pharmacology or dosing evidence, mechanistic plausibility cannot be independently confirmed here.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02770508 | Phase 4 | Completed | 145 | Compared ritonavir-boosted darunavir + lamivudine vs. boosted darunavir + emtricitabine/tenofovir or lamivudine/tenofovir in treatment-naïve human HIV-1 patients. Note: this trial studies human HIV-1, not feline AIDS; relevance grading is still marked "pending" in source data. |
Literature Evidence
Currently no related literature available for this predicted indication (feline acquired immunodeficiency syndrome).
Taiwan Market Information
No authorization records available — ritonavir is not currently marketed in Taiwan per this evidence pack (total_licenses: 0).
Safety Considerations
A Blocking-severity data gap (DG001) has been identified: TFDA package insert warnings and contraindications have not yet been retrieved, which means this candidate cannot proceed to S1 safety pre-assessment until this is remediated. All other safety fields in this evidence pack (key warnings, contraindications, drug-drug interactions) are unpopulated (query_status: not_found).
Please refer to the package insert for safety information once available.
Conclusion and Next Steps
Decision: Hold
Rationale:
- A Blocking data gap (DG001 — missing TFDA label/warnings) explicitly prevents entry into safety pre-assessment (S1).
- The predicted indication is a non-human (feline) disease, and the sole supporting clinical trial does not actually study that indication; overall evidence level is L5.
- The drug is not currently marketed in Taiwan (0 authorizations), and MOA data needed to assess mechanistic plausibility is missing (DG002).
To proceed, the following is needed:
- Retrieve TFDA package insert (warnings/contraindications) to close DG001 (Blocking)
- Retrieve DrugBank MOA data to close DG002 (High)
- Clarify whether the TxGNN prediction for "feline acquired immunodeficiency syndrome" reflects a genuine repurposing signal or a cross-species knowledge-graph artifact before further evaluation
- Complete relevance grading for the pending trial/literature classifications (also consider re-reviewing rank 2, "simian immunodeficiency virus infection," which has more literature but remains an animal-model indication)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.